country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-182346

Copy Link Print Information

FBPase-IN-7

FBPase-IN-7 is a fructose-1,6-bisphosphatase (FBPase) inhibitor with an IC₅₀ of 0.75 μM. FBPase-IN-7 binds to a cryptic allosteric pocket of FBPase, induces conformational rearrangement of key residues, forms a hydrogen-bond network, and disrupts substrate catalysis. FBPase-IN-7 confirms cellular stabilizes HuFBPase in hepatic cells. FBPase-IN-7 has hypoglycemic activity. FBPase-IN-7 can be used for the research of type 2 diabetes.

For research use only. We do not sell to patients.

Formula: C₂₃H₁₅F₂N₃O₆S₂
Molecular Weight:531.51

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

FBPase-IN-7 Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

FBPase-IN-7 (Compound 29) potently inhibits purified human fructose-1,6-bisphosphatase (FBPase) with an IC₅₀ of 0.75 μM^[1].
FBPase-IN-7 (20 μM) directly engages HuFBPase in LO2 human liver cells, conferring a thermal stabilization^[1].
FBPase-IN-7 (24 h) shows minimal cytotoxicity in LO2 human liver cells and HEK293T human embryonic kidney cells, with EC₅₀ values >50 μM for both cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

FBPase-IN-7 (Compound 29) (100 mg/kg; i.p.; single dose) produces meaningful glycemic control in vivo, reducing the 0-1.5 h blood glucose area under the curve by 20.6% in fasted ICR mice subjected to an oral glucose tolerance test^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICR mice with glucose challenge (2 g/kg) (male, 20-24 g, 12 h-fasted, oral glucose tolerance test model)^[1]
Dosage:

100 mg/kg
Administration:

i.p.; single dose
Result:

Reduced the blood glucose AUC_0-1.₅ₕ by 20.6%.

Chemical Information

Molecular Weight 531.51
Formula C₂₃H₁₅F₂N₃O₆S₂
SMILES

O=C(NC1=CC=C(S(NC(NC2=CC=C3OC(F)(OC3=C2)F)=O)(=O)=O)C=C1)C4=CSC5=C4C=CC=C5
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Huang Z, et al. Crystallographic Study Reveals a Cryptic Allosteric Site of FBPase by Sulfonylurea Inhibitors toward T2DM Treatment. J Med Chem. 2026;69(6):7200-7213. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote